Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935818 · ClinicalTrials.gov registry record · Phase 2
Varenicline and Bupropion for Smoking Cessation
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 506
- Enrollment target
NCT00935818: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00935818 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 506 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00935818, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 506 participants
- Enrollment target
Study Summary
This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.
Primary Outcome
Prolonged smoking abstinence is defined as no smoking, not even a puff, in the last 7 days, and a negative response to the question "Since 2 weeks after your target quit date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?"
Interventions
- DRUG placebo
- DRUG Varenicline
- DRUG bupropion SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00935818 record still lists
NCT00935818 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00935818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00935818 about?
NCT00935818 is a clinical study titled "Varenicline and Bupropion for Smoking Cessation". This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.
What is the current status of trial NCT00935818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 506 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00935818?
The interventions under investigation include: placebo (DRUG), Varenicline (DRUG), bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00935818?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00935818's enrollment target sits among peer trials
506 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia